Dr. Sanford T. Ward, D.O. Allergy & Immunology - Allergy Medicare: Not Enrolled in Medicare Practice Location: 835 Se Bishop Blvd Ste 601, Pullman, WA 99163 Phone: 509-334-5876 Fax: 509-332-8793 |
News Archive
The US Food and Drug Administration has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease (ECD).
Federal Trade Commission Chairman Jon Leibowitz told a meeting of 300 health industry representatives Tuesday his agency would explore an 'expedited review process' for hospitals and doctors looking to determine if new partnerships they form to provide care would violate antitrust laws. He was one of several top federal officials trying to address the concerns of hospitals and doctors.
CPEX Pharmaceuticals Inc. today announced that its partner, Serenity Pharmaceuticals, has entered into a global agreement with Allergan, Inc. for the development and commercialization of Ser-120, a product candidate currently in Phase III clinical trials for the treatment of nocturia that utilizes CPEX's patented intranasal drug delivery technology.
The Wall Street Journal examines global efforts to stop the spread of drug-resistant tuberculosis (TB) strains, stating, "Global health officials view the emergence of incurable cases of tuberculosis in India as a worrisome evolution in a trend they have been concerned and intensely frustrated about for years - the rise of drug resistant forms of tuberculosis around the world."
The researchers evaluated data over a 36-year period from the National Hospital Discharge Survey and concluded in a paper appearing in the January issue of Archives of Surgery that appendicitis may be caused by undetermined viral infection or infections, said Dr. Edward Livingston, chief of GI/endocrine surgery at UT Southwestern and senior author of the report.
› Verified 8 days ago